A Case of NCAM1-Positive Lupus Nephritis with NCAM1 Antibody Titers Responsive to Rituximab.

IF 2.3 4区医学 Q2 UROLOGY & NEPHROLOGY

Nephron Pub Date : 2024-01-01 Epub Date: 2023-09-29 DOI:10.1159/000534037

Yifeng Wang, Ruiying Chen, Min Han, Shaojun Liu, Qionghong Xie, ChuanMing Hao

引用次数: 0

Abstract

Neural cell adhesion molecule 1 (NCAM1) is a recently identified new antigen of membranous nephropathy (MN) mostly secondary to systemic lupus erythematosus with a low positive rate of 6.6%, and its corresponding antibody was detected in patients' sera. Here, we reported a case of NCAM1-positive lupus nephritis (class V+III) developed from MN. The patient was refractory to multiple immunosuppressive regimens but achieved remission after the application of rituximab as an add-on therapy and showed a reduction of anti-NCAM1 antibody and proteinuria.

查看原文本刊更多论文

一例NCAM1阳性狼疮性肾炎，NCAM1抗体滴度对利妥昔单抗有反应。

NCAM1是最近发现的膜性肾病（MN）的一种新抗原，主要继发于系统性红斑狼疮（SLE），其阳性率较低，为6.6%，并在患者血清中检测到相应的抗体。在这里，我们报告了一例由MN发展而来的NCAM1阳性狼疮性肾炎（Ⅴ+Ⅲ类）。该患者对多种免疫抑制方案具有难治性，但在应用利妥昔单抗作为附加治疗后获得了缓解，并显示抗NCAM1抗体和蛋白尿的减少。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nephron UROLOGY & NEPHROLOGY-

CiteScore

5.00

自引率

0.00%

发文量

期刊介绍： ''Nephron'' comprises three sections, which are each under the editorship of internationally recognized leaders and served by specialized Associate Editors. Apart from high-quality original research, ''Nephron'' publishes invited reviews/minireviews on up-to-date topics. Papers undergo an innovative and transparent peer review process encompassing a Presentation Report which assesses and summarizes the presentation of the paper in an unbiased and standardized way.